Johnson & Johnson Fined $2.2 Billion: Marketed Risperdal For Off-Label Use
By Marilyn T. McGoldrick, Esq. Posted on Nov 15, 2013 Although only approved by the Food and Drug Administration for certain patients with specific psychiatric disorders, Johnson & Johnson marketed Risperdal for a variety of non-approved, “off label,” uses. This...
Reports: Johnson & Johnson Will Pay $4B In DePuy ASR Settlements
Posted by Marilyn McGoldrick on Nov 13, 2013 10:30:00 AM Today there are multiple news reports of great interest to people suffering from defective hip replacements: Johnson & Johnson’s subsidiary DePuy Orthopaedics has agreed to a tentative settlement of over 4...
Verdict: J&J Must Pay $4M For Oral Cleft Birth Defects From Topamax
Posted by Marilyn McGoldrick on Nov 5, 2013 3:30:00 AM Johnson & Johnson’s Janssen Pharmaceutical unit has been ordered to pay $4.02 million in a lawsuit claiming its anti-seizure drug Topamax was responsible for a child’s birth defect, a Philadelphia jury said...
